ArticleScientific reports2025
Unveiling potent xanthine oxidase inhibitors in two Balanophora spp. using machine learning-based virtual screening and molecular docking approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating Artificial Intelligence Into Drug Discovery From Medicinal Plants: Current Applications and Infrastructural Challenges.Chemical biology & drug design · 2026Review
- Phytochemical, Antimicrobial, Insect-Repellent, and Molecular Docking Profiles of Gamma-IrradiatedMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological studies revealed that the Balanophora species contains diverse phytochemicals which enable interesting biological activities and emphasize their pharmaceutical relevance. Previously, we identified significant xanthine oxidase (XO) inhibitory activity from extracts of the two Balanophora spp. (Balanophora subcupularis P.C. Tam and Balanophora tobiracola Makino). However, the specific compounds responsible for this activity remain unidentified so far. Thus, in the present study, we focused on elucidating the compounds inducing the XO inhibitory effect of extracts from Balanophora species. Therefore, a combination of advanced liquid chromatography and mass spectrometry (LC-QToF-HRMS), virtual screening using machine learning (ML) models, and molecular docking simulation was applied. Using LC-QToF-HRMS, 23 and 21 compounds were identified in the ethyl acetate fractions of B. subcupularis and B. tobiracola, respectively. Next, a curated dataset of natural and synthetic compounds with known XO inhibitory activity was employed to train several ML models. Adducing five selected ML models, the virtual screening process identified the potentially active compounds 1-(3,4-dihydroxyphenyl)-6,7-dihydroxy-1,2-dihydro-2,3-naphthalenedicarboxylic acid, taxifolin, and 1-O-caffeoyl-6-O-(S)-brevifolincarboxyl-β-D-glucopyranose. All the compounds found in the two Balanophora spp. underwent docking simulations, in which MTE, FES, and AFH were retained in the active site of XO, ensuring reliable re-docking results. Finally, taxifolin emerged as the most promising novel XO inhibitor, demonstrating greater potential than the established drug allopurinol, as supported by both the virtual screening nomination and docking simuation. These findings contribute to the development of natural XO inhibitors and may open new opportunities for gout treatment and uric acid level control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.